BR112012019267B1 - Composição englobando célula dendrítica (dc) madura próinflamatória, e uso da dita célula - Google Patents

Composição englobando célula dendrítica (dc) madura próinflamatória, e uso da dita célula Download PDF

Info

Publication number
BR112012019267B1
BR112012019267B1 BR112012019267-1A BR112012019267A BR112012019267B1 BR 112012019267 B1 BR112012019267 B1 BR 112012019267B1 BR 112012019267 A BR112012019267 A BR 112012019267A BR 112012019267 B1 BR112012019267 B1 BR 112012019267B1
Authority
BR
Brazil
Prior art keywords
cells
inflammatory
dcs
tumor
pro
Prior art date
Application number
BR112012019267-1A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012019267A2 (pt
Inventor
Karlsson-Parra Alex
Andersson Bengt
Wallgren Annacarin
Original Assignee
Immunicum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunicum Ab filed Critical Immunicum Ab
Publication of BR112012019267A2 publication Critical patent/BR112012019267A2/pt
Publication of BR112012019267B1 publication Critical patent/BR112012019267B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4532—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012019267-1A 2010-02-10 2011-02-10 Composição englobando célula dendrítica (dc) madura próinflamatória, e uso da dita célula BR112012019267B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30315310P 2010-02-10 2010-02-10
SE1050133 2010-02-10
SE1050133-6 2010-02-10
US61/303,153 2010-02-10
PCT/EP2011/051952 WO2011098516A1 (en) 2010-02-10 2011-02-10 Improved composition for inhibiting tumor cell proliferation

Publications (2)

Publication Number Publication Date
BR112012019267A2 BR112012019267A2 (pt) 2020-10-06
BR112012019267B1 true BR112012019267B1 (pt) 2022-03-03

Family

ID=43903832

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012019267-1A BR112012019267B1 (pt) 2010-02-10 2011-02-10 Composição englobando célula dendrítica (dc) madura próinflamatória, e uso da dita célula

Country Status (13)

Country Link
US (1) US9034317B2 (enExample)
EP (1) EP2534242B1 (enExample)
JP (1) JP5855018B2 (enExample)
KR (1) KR101770785B1 (enExample)
CN (1) CN102782123B (enExample)
BR (1) BR112012019267B1 (enExample)
DK (1) DK2534242T3 (enExample)
ES (1) ES2581277T3 (enExample)
HU (1) HUE028352T2 (enExample)
PL (1) PL2534242T3 (enExample)
RU (1) RU2565542C2 (enExample)
SI (1) SI2534242T1 (enExample)
WO (1) WO2011098516A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2591230T3 (es) 2012-12-18 2016-11-25 Immunicum Ab Co-diferenciación y activación de monocitos procedentes de donantes alogénicos para producir células dendríticas pro-inflamatorias
AU2016259020B2 (en) * 2015-05-07 2021-12-09 Baylor College Of Medicine Dendritic cell immunotherapy
CN105695403A (zh) * 2015-12-31 2016-06-22 深圳市中美康士生物科技有限公司 一种杀伤性免疫细胞的培养方法及其应用
CN105462926A (zh) * 2015-12-31 2016-04-06 深圳市中美康士生物科技有限公司 一种免疫细胞瘤苗的制备方法及其应用
CN107574149B (zh) * 2016-07-05 2022-02-18 上海细胞治疗研究院 一种树突状细胞的促成熟方法及其用途
CN106085960A (zh) * 2016-07-28 2016-11-09 广州赛莱拉干细胞科技股份有限公司 一种培养dc细胞的培养基及培养方法
CA3037882A1 (en) * 2016-09-23 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
GB201711379D0 (en) 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
SI3460052T1 (sl) * 2017-09-20 2020-03-31 Immunicum Ab Izboljšane alogene dendritične celice za uporabo pri zdravljenju raka

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
WO2004053072A2 (en) * 2002-12-06 2004-06-24 Northwest Biotherapeutics, Inc. Administration of dendritic cells partially matured in vitro for the treatment of tumors
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
WO2008110569A1 (en) 2007-03-12 2008-09-18 Bioneer A/S Method for determination of immunomodulatory effect
CN101883845B (zh) 2007-10-08 2015-06-10 英特瑞克斯顿股份有限公司 工程树突细胞及其在癌症治疗中的应用
WO2010065876A2 (en) * 2008-12-06 2010-06-10 The Board Of Regents Of The University Of Texas System Methods and compositions related to th-1 dendritic cells
CN101481677B (zh) * 2009-01-22 2011-12-14 复旦大学附属华山医院 体外刺激树突状细胞成熟的方法

Also Published As

Publication number Publication date
DK2534242T3 (en) 2016-07-18
EP2534242A1 (en) 2012-12-19
WO2011098516A1 (en) 2011-08-18
RU2565542C2 (ru) 2015-10-20
PL2534242T3 (pl) 2016-11-30
US20120328662A1 (en) 2012-12-27
BR112012019267A2 (pt) 2020-10-06
HUE028352T2 (en) 2016-12-28
JP5855018B2 (ja) 2016-02-09
CN102782123A (zh) 2012-11-14
SI2534242T1 (sl) 2016-08-31
CN102782123B (zh) 2016-05-11
KR20120114358A (ko) 2012-10-16
KR101770785B1 (ko) 2017-08-23
ES2581277T3 (es) 2016-09-05
JP2013519363A (ja) 2013-05-30
US9034317B2 (en) 2015-05-19
EP2534242B1 (en) 2016-04-20
RU2012137173A (ru) 2014-03-20

Similar Documents

Publication Publication Date Title
BR112012019267B1 (pt) Composição englobando célula dendrítica (dc) madura próinflamatória, e uso da dita célula
Liau et al. Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigens
ES2535835T3 (es) Composiciones para la preparación de células dendríticas maduras
Singh et al. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma
BR112020004221A2 (pt) célula dendrítica pró-inflamatória, composição farmacêutica, e, método para prover células dendríticas pró-inflamatórias
US20230226218A1 (en) Red Cell Extracellular Vesicles (RCEVs) Containing Cargoes and Methods of Use and Production Thereof
BRPI0817535B1 (pt) método in vitro eficiente para obter células apresentadoras de antígenos ativadas (apcs), especialmente células dendríticas (dcs), úteis na preparação de vacinas para o tratamento do câncer
WO2018137643A1 (zh) 溶瘤病毒作为用于治疗肿瘤和/或癌症的免疫刺激剂的应用
JP2018537478A (ja) 小分子アブレーション化合物を用いたがん免疫治療のための生体外（Ｅｘ Ｖｉｖｏ：エクスビボ）での免疫細胞活性の増強方法
Yan et al. Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles
Zhang et al. Integration of Protein Nanocage with CpG Motifs: A Virus‐Mimicked Core‐Shell Nanostructure to Ignite Antitumor Immunity
Svensson et al. mRNA-LNP vaccine strategies: Effects of adjuvants on non-parenchymal liver cells and tolerance
IL292009A (en) In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response
Yin et al. A novel therapeutic vaccine of GM-CSF/TNFα surface-modified RM-1 cells against the orthotopic prostatic cancer
Zhu et al. Intranodal injection of neoantigen-bearing engineered Lactococcus lactis triggers epitope spreading and systemic tumor regressions
Shi et al. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer
Hu et al. A two-pronged strategy utilizing exosomes extracted from antigen-presenting cells to combat hepatitis B
JP7146732B2 (ja) 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法
Jacobs et al. Endocrine organs under the control of the immune system: potential implications for cellular therapies
Wang et al. FlaB-expressing bacterial uter membrane vesicles vaccine mediating anti-tumor immune response via promoting DCs activation and lymph nodes-homing.
EP3113783A1 (en) A composition comprising ex-vivo generated dendritic cells
HK1256146A1 (zh) 溶瘤病毒作为用於治疗肿瘤和/或癌症的免疫刺激剂的应用
JP2002212099A (ja) 腫瘍ワクチン
AU2008280436A1 (en) Compositions and methods for generating an immune response in a subject

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/02/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.